08:50-09:00 | Opening Remark | ¡¡ |
Session¥° Biomarker and Drug Discovery of Sarcopenia ÁÂÀå: ÀåÇÐö(¼¿ïÀÇ´ë), ·ùµ¿·Ä(GIST) |
||
09:00-09:25 | Exploring Sarcopenia Biomarkers and Therapeutic Targets Through Animal Models | ±è¹üÁØ ±³¼ö (¿ï»êÀÇ´ë) |
09:25-09:50 | Mitochondrial Metabolic Reprogramming to Combat Sarcopenia | °Á¾¼ø ±³¼ö (¼º±Õ°ü´ë) |
09:50-10:15 | Serotonin: A Novel Therapeutic Target for Sarcopenia | ¿Àâ¸í ±³¼ö (GIST) |
Session ¥± Keynote Session ÁÂÀå: ±è´öÀ± (°æÈñÀÇ´ë) |
||
10:15-10:50 | Targeting the GDF15-GFRAL Axis in the Dorsal Vagal Complex with a Dual Therapeutic Strategy for Cancer-associated Cachexia | ¼Û¹ÎÈ£ ±³¼ö (KAIST) |
10:50-11:00 | Coffee Break | ¡¡ |
Session ¥² Cachexia and Sarcopenia in Older Adults with Cancer ÁÂÀå: ¹ÚÇü¹« (±×·¹À̽ºº´¿ø), °í¼¼ÀÏ (°æ»óÀÇ´ë) |
||
11:00-11:25 | Cancer Cachexia | ³ë¿ëÈ£ ±³¼ö (Áß¾ÓÀÇ´ë) |
11:25-11:50 | Sarcopenia and Cancer | ¹Ú¼ÛÀÌ ±³¼ö (Áß¾ÓÀÇ´ë) |
11:50-12:15 | Combatting Cancer-Related Muscle Wasting: New Insights and Therapies for Cachexia and Sarcopenia | °í¼¼ÀÏ ±³¼ö (°æ»óÀÇ´ë) |
12:15-12:30 | Discussion | ¡¡ |
Luncheon Symposium & Lunch ÁÂÀå: ±èųâ (ÀÎÁ¦ÀÇ´ë) |
||
12:30-13:30 | 1. ±Ù°¨¼ÒÁõ ȯÀÚ¿¡¼ Å×½ºÅ佺Å×·ÐÀÇ »ç¿ë 2. ½º¸¶Æ® ÀμÖÀ» ÀÌ¿ëÇÑ ±Ù°¨¼ÒÁõ ȯÀÚ °ü¸® |
À¯ÁØÀÏ ±³¼ö (ÀÎÇÏÀÇ´ë) |
Session IV Muscle Loss in Obesity Treatment: Challenges and Strategies ÁÂÀå: ¿øÀå¿ø (°æÈñÀÇ´ë), È«¼ººó (ÀÎÇÏÀÇ´ë) |
||
13:30-14:00 | Understanding Muscle Loss during Weight Loss: Mechanisms and Risk Factors | ¹Ú°è¿µ ±³¼ö (ÇѾçÀÇ´ë) |
14:00-14:30 | Body composition changes induced by GLP-1RA-based therapies: Impact of muscle loss on health outcomes | ¹èÀçÇö ±³¼ö (¼¿ïÀÇ´ë) |
14:30-15:00 | Preventing and Managing Muscle Loss in Obesity: Current Approaches and Future Directions | ÀÌÁØ¿± ±³¼ö (Ä«Å縯ÀÇ´ë) |
15:00-15:20 | Coffee Break | ¡¡ |
Session ¥´ Interventional Management of Sarcopenia ÁÂÀå: ¹Ú¿ë¼ø (ÇѾç´ëÇб³), ¹ÚÇöÅ (µ¿¾Æ´ëÇб³) |
||
15:20-15:45 | Exercise and Rehabilitation Strategies for Sarcopenia Management | ±èÁö¿¬ ±³¼ö (°¡Ãµ´ëÇб³) |
15:45-16:10 | Nutritional Interventions to Mitigate Muscle Loss | ±èÇö¼÷ ±³¼ö (ÇѾç´ëÇб³) |
16:10-16:35 | Digital Therapeutics and AI-driven Solutions for Sarcopenia Treatment | Áö¼ºÈ¯ ¿¬±¸¿ø (»ï¼ºÀ¶ÇÕÀÇ°úÇпø) |
16:35-16:50 | ±¸¿¬ ¹× Æ÷½ºÅÍ ½Ã»ó ¹× Á¤±â ÃÑȸ | ¡¡ |
Session VI ÀÚÀ¯¿¬Á¦ ÁÂÀå: ÇÏ¿ëÂù (ºÎ¹Îº´¿ø), ÀÌ¿µ±Õ (¼¿ïÀÇ´ë) |
||
09:30-10:15 | ÀÚÀ¯ ¿¬Á¦ | |
Session VII Advances in Tissue Engineering and Biomaterials for Musculoskeletal Regeneration ÁÂÀå: ÀÌÀ±½Ç(¼¿ï´ëÇб³ Ä¡°ú´ëÇÐ), ±èÁ¤Àº(°æºÏÀÇ´ë) |
||
11:00-11:30 | Development of Muscle Models in Microphysiological System | Àü¼ºÀ± ±³¼ö (KAIST) |
11:30-12:00 | Advanced Tissue Engineering for Muscle Regeneration | Á¶½Â¿ì ±³¼ö (¿¬¼¼ÀÇ´ë) |
12:00-12:30 | Adhesive Hydrogel Electrodes for Peripheral Nerve and Muscle Interfaces | ½Å¹Ì°æ ±³¼ö (¼º±Õ°ü´ëÇб³) |
Luncheon Symposium & Lunch ÁÂÀå: ±èųâ (ÀÎÁ¦ÀÇ´ë) |
||
12:30-13:30 | 1. ±Ù°¨¼ÒÁõ ȯÀÚ¿¡¼ Å×½ºÅ佺Å×·ÐÀÇ »ç¿ë 2. ½º¸¶Æ® ÀμÖÀ» ÀÌ¿ëÇÑ ±Ù°¨¼ÒÁõ ȯÀÚ °ü¸® |
À¯ÁØÀÏ ±³¼ö (ÀÎÇÏÀÇ´ë) |
Session VIII Emerging Therapeutic Targets for Sarcopenia ÁÂÀå: ±èÀÏ¿µ(°¡ÃµÀÇ´ë), ÀüÀçÇÑ(¾Æº¥Æ¼) |
||
13:30-14:00 | Exercise-induced CLCF1 Reverses Age-related Skeletal Muscle and Bone Decline | ¾ç¿ë·Ä ¹Ú»ç (Çѱ¹»ý¸í°øÇבּ¸¿ø) |
14:00-14:30 | Identification and Validation of MASAP as a Universal Blood Biomarker for Sarcopenia | Á¶À±ÁÖ ¹Ú»ç (GIST) |
14:30-15:00 | Protein Arginine Methyltransferase 1 is Essential for Neuromuscular Junction and Mitochondrial Homeostasis Via Mitophagy Regulation | ¹èÁÖÇö ¹Ú»ç(¼º±Õ°ü´ëÇб³) |
15:00-15:20 | Coffee Break | ¡¡ |
Session IX Respiratory Sarcopenia: Concepts, Evaluation, and Training Approaches ÁÂÀå: ±èµ·±Ô (Áß¾ÓÀÇ´ë), ÀÓÀ翵 (¼¿ïÀÇ´ë) |
||
15:20-15:50 | Defining Respiratory Sarcopenia: Cutoff Values Using MIP and MEP | ½Å¸íÁØ ±³¼ö (ºÎ»êÀÇ´ë) |
15:50-16:20 | Assessment and Training Methods for Respiratory Muscle Strength (MIP/MEP) | ¹Úżº ±³¼ö (ºÎ»ê´ëÇб³º´¿ø) |
16:20-16:30 | Discussion |